Nayar, Saba; Campos, Joana; Smith, Charlotte G; Iannizzotto, Valentina; Gardner, David H; Colafrancesco, Serena; Pipi, Elena; Kollert, Florian Kim; Hunter, Kelly J; Brewer, Charlotte; Buckley, Christopher Dominic; Bowman, Simon J; Priori, Roberta; Valesini, Guido; Juarez, Maria; Fahy, William A; Fisher, Benjamin A; Payne, Andrew; Allen, Rodger A and Barone, Francesca (2019). Phosphatidylinositol 3-kinase delta pathway: a novel therapeutic target for Sjögren's syndrome. Annals of the rheumatic diseases, 78(2), pp. 249-260. BMJ Publishing Group 10.1136/annrheumdis-2017-212619
|
Text
249.full.pdf - Published Version Available under License Creative Commons: Attribution (CC-BY). Download (2MB) | Preview |
BACKGROUND
The phosphatidylinositol 3-kinase delta isoform (PI3Kδ) belongs to an intracellular lipid kinase family that regulate lymphocyte metabolism, survival, proliferation, apoptosis and migration and has been successfully targeted in B-cell malignancies. Primary Sjögren's syndrome (pSS) is a chronic immune-mediated inflammatory disease characterised by exocrine gland lymphocytic infiltration and B-cell hyperactivation which results in systemic manifestations, autoantibody production and loss of glandular function. Given the central role of B cells in pSS pathogenesis, we investigated PI3Kδ pathway activation in pSS and the functional consequences of blocking PI3Kδ in a murine model of focal sialoadenitis that mimics some features of pSS.
METHODS AND RESULTS
Target validation assays showed significant expression of phosphorylated ribosomal protein S6 (pS6), a downstream mediator of the phosphatidylinositol 3-kinase delta (PI3Kδ) pathway, within pSS salivary glands. pS6 distribution was found to co-localise with T/B cell markers within pSS aggregates and the CD138+ plasma cells infiltrating the glands. In vivo blockade of PI3Kδ activity with seletalisib, a PI3Kδ-selective inhibitor, in a murine model of focal sialoadenitis decreased accumulation of lymphocytes and plasma cells within the glands of treated mice in the prophylactic and therapeutic regimes. Additionally, production of lymphoid chemokines and cytokines associated with ectopic lymphoneogenesis and, remarkably, saliva flow and autoantibody production, were significantly affected by treatment with seletalisib.
CONCLUSION
These data demonstrate activation of PI3Kδ pathway within the glands of patients with pSS and its contribution to disease pathogenesis in a model of disease, supporting the exploration of the therapeutic potential of PI3Kδ pathway inhibition in this condition.
Item Type: |
Journal Article (Original Article) |
|---|---|
Division/Institute: |
04 Faculty of Medicine > Department of Dermatology, Urology, Rheumatology, Nephrology, Osteoporosis (DURN) > Clinic of Rheumatology and Immunology |
UniBE Contributor: |
Kollert, Florian Kim |
Subjects: |
600 Technology > 610 Medicine & health |
ISSN: |
0003-4967 |
Publisher: |
BMJ Publishing Group |
Language: |
English |
Submitter: |
Burkhard Möller |
Date Deposited: |
26 Jul 2019 09:19 |
Last Modified: |
05 Dec 2022 15:25 |
Publisher DOI: |
10.1136/annrheumdis-2017-212619 |
PubMed ID: |
30472652 |
Uncontrolled Keywords: |
B cells autoantibodies autoimmune diseases sjøgren's syndrome treatment |
BORIS DOI: |
10.7892/boris.125140 |
URI: |
https://boris.unibe.ch/id/eprint/125140 |
Actions (login required)
 |
Edit item |